AMPH Q4 2019 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$83M-7.0% YoY

Gross Profit

$33M40.0% margin

Operating Income

-$244,000-0.3% margin

Net Income

-$1M-1.2% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

-$3M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$587M

Total Liabilities

$159M

Stockholders' Equity

$381M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$90M	-7.0%
Gross Profit	$33M	$35M	-3.8%
Operating Income	-$244,000	$2M	-115.8%
Net Income	-$1M	$2M	-155.0%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$5M100%

Geographic Segments

U

$78M99%

C

$438,0001%